Arvinas, Inc. (ARVN)


+1.47 (+4.50%)
Symbol ARVN
Price $34.16
Beta 1.940
Volume Avg. 0.62M
Market Cap 1.880B
Shares () -
52 Week Range 13.57-39.31
1y Target Est -
DCF Unlevered ARVN DCF ->
DCF Levered ARVN LDCF ->
ROE -58.36% Strong Sell
ROA -27.53% Sell
Operating Margin -
Debt / Equity 0.87% Neutral
P/E -6.19 Strong Sell
P/B 4.04 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest ARVN news

Dr. John G. Houston Ph.D.
NASDAQ Global Select

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.